Oncoinvent (ONCIN) Q1 2025 earnings summary

Executive summary

• Radspherin, a targeted, non-biologic, receptor-independent alpha-emitting radiopharmaceutical, is in phase 2 development for peritoneal metastases in ovarian and colorectal cancers, addressing high unmet medical needs with limited competition.

• Positive safety and efficacy signals observed in both phase 1 and phase 2 studies, with encouraging clinical data supporting potential as a game changer.

• The company is led by an experienced management team with a strong track record in radiopharmaceutical development and commercialization.

Financial highlights

• Cash and cash equivalents totaled NOK 105 million as of March 31, 2025, expected to fund operations into 2026.

• NOK 130 million was raised in a private placement and Euronext Growth listing in December, with an additional NOK 11 million from a subsequent offering.

• Financial management remains disciplined, with half-yearly rather than quarterly financial reporting.

Outlook and guidance

• Focus remains on advancing ovarian cancer trials, with interim and final data readouts scheduled through 2026.

• Recruitment speed for phase 2 is a key focus, with ongoing protocol amendments and site expansions to accelerate enrollment.

• Colorectal cancer development will resume when financial resources or partnerships allow.

• No material changes to operating cash burn are expected in the near term; the company is exploring strategic options to extend its cash runway, including partnerships and financing.